Seraxis, a private biotech company, is developing a cell therapy to cure insulin-dependent diabetes by replacing the beta cells of the pancreas. Their team of scientists created an induced Pluripotent Stem Cell (iPSC) line, that differentiates robustly into insulin-producing pancreatic cells. These cells are encapsulated to protect them from immune attacks and implanted in relevant models of type-1-diabetes. The safety and efficacy of the Seraxis therapy, SR-01, has been assessed in mice, rat and non-human primates in pre-clinical studies. The well-characterized and stable insulin-producing cells demonstrated a high level of purity, response to glucose challenge and secreted insulin over the 6 months of the studies. Additionally, Seraxis encapsulation technology was shown to efficiently protect these cells from the host immune destruction, while allowing vascularization and nutrition of the cells. In an on-going study, SR-01 has been shown to restore normal glycemic control in immune-competent diabetic rats for more than 3 months.

Shuttle Pharmaceuticals develops radiation sensitizing drugs to improve the outcomes of patients undergoing radiation therapy for cancer treatment. Clinical phase drug candidates include ropidoxuridine for sensitizing rapidly growing tumors and doranidazole for sensitizing hypoxic cancers that are resistant to radiation therapy.

Developing botulinum toxin and other neurotoxin productions. US Office for Medytox Inc.

Therapeutics and diagnostic company focused on pandemic diseases.

Immuno-oncology company developing CAR T-Cell Therapy for treatment of Cancer.

3I was founded in 2013 to develop a cost-effective, accurate, and easy-to-use diagnostic that would improve the effectiveness of antibiotics-related clinical decisions.

Epigenomics is a molecular diagnostics company focused on developing innovative screening tests for cancer. Our lead product, Epi proColon, is the first and only FDA-approved blood-based test for colorectal cancer.  In the US today, 1 in 3, or 23 million eligible people, are not screened for colorectal cancer.  Epi proColon provides a convenient blood-based option to address this non-screened population.

Developing a universal Pneumococcal vaccine. SynAm Vaccine’s lead universal vaccine candidate addresses the critical unmet medical need in the marketplace by providing universal coverage against all 91 bacteria serotypes, while current marketed vaccines cover only a fraction of the serotypes.

In August of 2009 fNIR Devices, LLC started its operations after licensing various technologies from the estate of Dr. Britton Chance and the Drexel University.  fNIR Devices offerings, a line of Continuous Wave Functional Near Infrared imaging tools, are capable of monitoring brain’s hemodynamics and thereby the cognitive state of the subject in natural environments. fNIR technology employs specific wavelengths in an optical frequency window that can easily pass through a few centimeters for most tissues allowing monitoring of blood oxygenation changes. The relative changes of light intensity across time provide the researchers with information about neural activity.   Todate with over 250 brain imagers in the field, fNIR Devices is the premier supplier of fNIR Spectroscopy imaging systems for research and other non-clinical applications.